ArticleResearch and practice in thrombosis and haemostasis2024

Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.

Víctor Jiménez-Yuste et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.